Detalles de la búsqueda
1.
Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus.
Arthritis Care Res (Hoboken);
74(11): 1822-1828, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-35439360
2.
Principles of Economic Evaluation in a Pandemic Setting: An Expert Panel Discussion on Value Assessment During the Coronavirus Disease 2019 Pandemic.
Pharmacoeconomics;
39(11): 1201-1208, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34557996
3.
Comparative analysis of long-term organ damage in patients with systemic lupus erythematosus using belimumab versus standard therapy: a post hoc longitudinal study.
Lupus Sci Med;
7(1)2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-33051264
4.
Organ damage in patients treated with belimumab versus standard of care: a propensity score-matched comparative analysis.
Ann Rheum Dis;
78(3): 372-379, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30610066
5.
Long-Term Impact of Belimumab on Health-Related Quality of Life and Fatigue in Patients With Systemic Lupus Erythematosus: Six Years of Treatment.
Arthritis Care Res (Hoboken);
71(6): 829-838, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30320964
6.
External Validation of Health Economic Decision Models for Chronic Obstructive Pulmonary Disease (COPD): Report of the Third COPD Modeling Meeting.
Value Health;
20(3): 397-403, 2017 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-28292484
7.
Patient Heterogeneity in Health Economic Decision Models for Chronic Obstructive Pulmonary Disease: Are Current Models Suitable to Evaluate Personalized Medicine?
Value Health;
19(6): 800-810, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-27712708
8.
Cost-Effectiveness of Glycopyrronium Bromide Compared with Tiotropium in Patients with Chronic Obstructive Pulmonary Disease in Sweden.
Appl Health Econ Health Policy;
13(6): 637-45, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-26324401
9.
Cost-effectiveness of the LABA/LAMA dual bronchodilator indacaterol/glycopyrronium in a Swedish healthcare setting.
Respir Med;
108(12): 1786-93, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-25307414
10.
Cost-effectiveness models for chronic obstructive pulmonary disease: cross-model comparison of hypothetical treatment scenarios.
Value Health;
17(5): 525-36, 2014 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-25128045
11.
Cost-effectiveness of rivaroxaban versus warfarin for stroke prevention in atrial fibrillation in the Belgian healthcare setting.
Pharmacoeconomics;
31(10): 909-18, 2013 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-24030788
12.
A UK-based cost-utility analysis of indacaterol, a once-daily maintenance bronchodilator for patients with COPD, using real world evidence on resource use.
Appl Health Econ Health Policy;
11(3): 259-74, 2013 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-23529714
13.
Improving clinical reality in chronic obstructive pulmonary disease economic modelling : development and validation of a micro-simulation approach.
Pharmacoeconomics;
31(2): 151-61, 2013 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-23329431
14.
Ipilimumab in 2nd line treatment of patients with advanced melanoma: a cost-effectiveness analysis.
J Med Econ;
16(2): 202-12, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-23057750
15.
The Cost-Effectiveness and Budget Impact of Introducing Indacaterol into the Colombian Health System.
Value Health Reg Issues;
1(2): 165-171, 2012 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-29702896
16.
Cost-utility analysis of indacaterol in Germany: a once-daily maintenance bronchodilator for patients with COPD.
Respir Med;
105(11): 1635-47, 2011 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-21764277
17.
Cost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: results for the non-squamous histology population.
BMC Cancer;
10: 26, 2010 Jan 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-20113499
Resultados
1 -
17
de 17
1
Próxima >
>>